Jacobs Levy Equity Management
NMRA icon

Jacobs Levy Equity Management’s Neumora Therapeutics NMRA Stock Holding History

Jacobs Levy Equity Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$534K Sell
273,870
-200,610
-42% -$520K ﹤0.01% 818
2025
Q4 		$849K Sell
474,480
-356,338
-43% -$780K ﹤0.01% 713
2025
Q3 		$1.51M Buy
+830,818
New +$1.34M 0.01% 642

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Jacobs Levy Equity Management's NMRA Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Neumora Therapeutics (NMRA) stake by 42% in Q1 2026, selling an estimated $520K and leaving 273,870 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Jacobs Levy Equity Management first reported a position in NMRA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.51M in Q3 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Jacobs Levy Equity Management held 273,870 shares of Neumora Therapeutics worth $534K as of Q1 2026.
  • Jacobs Levy Equity Management sold 200,610 Neumora Therapeutics shares in Q1 2026, an estimated $520K.
  • Neumora Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #818 holding.
  • Jacobs Levy Equity Management first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jacobs Levy Equity Management's Neumora Therapeutics position peaked at $1.51M in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.